Data gathered: November 14
Alternative Data for Gyre Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 59 | Sign up | Sign up | Sign up |
| Webpage traffic | 1,000 | Sign up | Sign up | Sign up |
| Google Trends | 12 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 155 | Sign up | Sign up | Sign up |
| Twitter Mentions | 17 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Gyre Therapeutics
None
| Price | $13.84 |
| Target Price | Sign up |
| Volume | 66,400 |
| Market Cap | $1.5B |
| Year Range | $9.36 - $19.01 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business UpdateNovember 12 - Yahoo |
Gyre Therapeutics : Reports Third Quarter 2024 and Year To Date Financial Results and Provides Business Update Form 8 KNovember 12 - Finnhub |
|
Gyre Therapeutics Breaks Above 200-Day Moving Average - Bullish for GYREOctober 24 - Market News Video |
|
 |
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 3.8% - Time to Sell?October 22 - Biztoc.com |
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver FibrosisOctober 22 - Finnhub |
|
 |
Renaissance Technologies LLC Makes New $166,000 Investment in Gyre Therapeutics, Inc. (NASDAQ:GYRE)October 14 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 26M | 18M | 25M | 2.9M | 4.2M | 0.000 |
| Q2 '24 | 26M | 19M | 24M | 4.5M | 3.3M | 0.034 |
| Q1 '24 | 55M | 17M | 26M | 9.9M | 8.2M | 0.032 |
| Q4 '23 | 190M | 73M | 26M | -82M | -92M | |
| Q3 '23 | 32M | 2.4M | 31M | 7.5M | 13M | -1.050 |
Insider Transactions View All
| USMAN NASSIM filed to sell 1,636 shares at $12. July 1 '24 |
| USMAN NASSIM filed to sell 1,636 shares at $15.6. May 2 '24 |
| USMAN NASSIM filed to sell 1,736 shares at $14.9. May 2 '24 |
| USMAN NASSIM filed to sell 6,736 shares at $13.9. May 2 '24 |
| USMAN NASSIM filed to sell 1,636 shares at $16.2. April 3 '24 |
Similar companies
Read more about Gyre Therapeutics (GYRE) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Gyre Therapeutics?
The Market Cap of Gyre Therapeutics is $1.5B.
What is the current stock price of Gyre Therapeutics?
Currently, the price of one share of Gyre Therapeutics stock is $13.84.
How can I analyze the GYRE stock price chart for investment decisions?
The GYRE stock price chart above provides a comprehensive visual representation of Gyre Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Gyre Therapeutics shares. Our platform offers an up-to-date GYRE stock price chart, along with technical data analysis and alternative data insights.
Does GYRE offer dividends to its shareholders?
As of our latest update, Gyre Therapeutics (GYRE) does not offer dividends to its shareholders. Investors interested in Gyre Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Gyre Therapeutics?
Some of the similar stocks of Gyre Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.